Importance of swift event adjudication of endpoints for adequate reporting to data and safety monitoring boards in clinical trials-lessons from CULPRIT-SHOCK

Trials. 2021 Mar 8;22(1):197. doi: 10.1186/s13063-021-05129-4.

Authors

Peter Clemmensen¹, Benedikt Schrage², Uwe Zeymer³, Holger Thiele⁴, Karl Wegscheider⁵

Affiliations

¹ University Heart and Vascular Center Hamburg, Department of Cardiology, Hamburg, Germany.
² University Heart and Vascular Center Hamburg, Department of Cardiology, Hamburg, Germany. b.schrage@uke.de.
³ Klinikum Ludwigshafen, Ludwigshafen am Rhein, Germany.
⁴ Heart Center Leipzig at University of Leipzig and Leipzig Heart Institute, Leipzig, Germany.
⁵ University Hospital Hamburg Eppendorf, Hamburg, Germany.

No abstract available

Publication types

Letter
Comment

MeSH terms

Clinical Trials Data Monitoring Committees*
Humans
Magnetic Resonance Imaging
Shock*